Colleen Kelley

1 week ago | ajmc.com | Julia Bonavitacola |Colleen Kelley

The prevention of HIV could monumentally shift followong the FDA approval of lenacapavir on June 19, as the twice-yearly long-acting injectable form of pre-exposure prophylaxis (PrEP) demonsstrated high efficacy in preventing HIV in early trials.

Mar 13, 2025 | contagionlive.com | John Parkinson |Colleen Kelley

Here is the first in a news series on the state of HIV today including prevention, funding, and newer modalities. HIV prevention in the form of pre-exposure prophylaxis (PrEP) continues to be a highly effective method of reducing the risk of contracting HIV.